Level and significance of plasma myeloperoxidase and the neutrophil to lymphocyte ratio in patients with coronary artery disease

Experimental and Therapeutic Medicine

Volumn 8, Issue 6, 2014, Pages 1951-1957

  Mayyas, Fadia A ^a   Al Jarrah, Mohammad I ^a,b   Ibrahim, Khalid S ^a,b   Alzoubi, Karem H ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^b KING ABDULLAH UNIVERSITY HOSPITAL   (Jordan)

Author keywords

Coronary artery disease; Myeloperoxidase; Myocardial infarction; Neutrophil

Indexed keywords

ACETYLSALICYLIC ACID; MYELOPEROXIDASE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY REPERFUSION; DIABETES MELLITUS; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INFLAMMATORY CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROTEIN DETERMINATION; ST SEGMENT ELEVATION;

EID: 84908158990     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.2034     Document Type: Article

References (25)

1. Fitchett DH, Theroux P, Brophy JM, et al: Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment-part 2: ST-segment elevation myocardial infarction. Can J Cardiol 27 (Suppl A): S402-S412, 2011.
2. Duivenvoorden R, Mani V, Woodward M, et al: Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study. JACC Cardiovasc Imaging 6: 1087-1094, 2013.
3. Naruko T, Ueda M, Haze K, et al: Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106: 2894-2900, 2002.
4. van der Wal AC, Becker AE, van der Loos CM and Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89: 36-44, 1994.
5. Mauriello A, Sangiorgi G, Fratoni S, et al: Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol 45: 1585-1593, 2005.
6. Kaya MG, Akpek M, Lam YY, et al: Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: a prospective, multicenter study. Int J Cardiol 168: 1154-1159, 2013.
7. Danesh J, Wheeler JG, Hirschfield GM, et al: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350: 1387-1397, 2004.
8. Zhang R, Brennan ML, Shen Z, et al: Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 277: 46116-46122, 2002.
9. Podrez EA, Schmitt D, Hoff HF and Hazen SL: Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 103: 1547-1560, 1999.
10. Zheng L, Nukuna B, Brennan ML, et al: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114: 529-541, 2004.
11. Vita JA and Loscalzo J: Shouldering the risk factor burden: infection, atherosclerosis, and the vascular endothelium. Circulation 106: 164-166, 2002.
12. Sugiyama S, Kugiyama K, Aikawa M, et al: Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 24: 1309-1314, 2004.
13. Tang WH, Wu Y, Nicholls SJ and Hazen SL: Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem 57: 33-39, 2011.
14. Proposal for the multinational monitoring of trends and determinants in cardiovascular disease and protocol (MONICA Project). WHO/MNC/82.1. Cardiovascular Disease Unit, World Health Organization, Geneva, 1982.
15. Cavusoglu E, Ruwende C, Eng C, et al: Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 99: 1364-1368, 2007.
16. Zhang R, Brennan ML, Fu X, et al: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286: 2136-2142, 2001.
17. Baldus S, Heeschen C, Meinertz T, et al; CAPTURE Investigators: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108: 1440-1445, 2003.
18. Chang LT, Chua S, Sheu JJ, et al: Level and prognostic value of serum myeloperoxidase in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J 73: 726-731, 2009.
19. Dominguez-Rodriguez A, Samimi-Fard S, Abreu-Gonzalez P, Garcia-Gonzalez MJ and Kaski JC: Prognostic value of admission myeloperoxidase levels in patients with ST-segment elevation myocardial infarction and cardiogenic shock. Am J Cardiol 101: 1537-1540, 2008.
20. Kaya MG, Yalcin R, Okyay K, et al: Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction. Tex Heart Inst J 39: 500-506, 2012.
21. Miura T: Direction of strategic use: a new classification of non-steroidal anti-inflammatory drugs based on reactivity with peroxidase. Yakugaku Zasshi 133: 681-689, 2013 (In Japanese).
22. Coimbra LS, Steffens JP, Muscará MN, Rossa C, Jr and Spolidorio LC: Antiplatelet drugs reduce the immunoinflammatory response in a rat model of periodontal disease. J Periodontal Res, 2013.
23. Eickmeier O, Seki H, Haworth O, et al: Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol 6: 256-266, 2013.
24. King M, Kingery JE and Casey B: Diagnosis and evaluation of heart failure. Am Fam Physician 85: 1161-1168, 2012.
25. Brügger-Andersen T, Hetland Ø, Ponitz V, Grundt H and Nilsen DW: The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction. Thromb Res 119: 415-421, 2007.